Aspeya
June 17, 2025
Company Presentation
153B
At Aspeya, we want to make a positive difference to people’s lives. We’re harnessing deep insight and scientific expertise to reimagine how ingredients can be used, and working towards the development and commercialization of a pipeline of wellness and healthcare products and brands. Aspeya operates as a separate company under the ownership of Philip Morris International and benefits from access to the oral technology platform of Fertin Pharma, a contract development and manufacturing organization (CDMO) that is a wholly owned subsidiary of Aspeya. Fertin Pharma develops and manufactures innovative oral and intra-oral delivery systems. We’re applying our expertise to innovate in the field of wellness and healthcare in four areas of focus: Cannabinoids Inhaled therapeutics Nicotine replacement therapy (NRT) Consumer health
Company HQ City:
Lausanne
Company HQ State:
Vaud
Company HQ Country:
Switzerland
Year Founded:
2025 (previously under the name of VecturaFertin Pharma)
Lead Product in Development:
-
CEO
Michael Kunst
Development Phase of Lead Product
Multiple Products in Market
What is your next catalyst (value inflection) update?
-
Website
www.aspeya.com
Primary Speaker


